This is a quote from Dr Andtbacker from 2 years ago. We have great results as per the quote but half the valuation from the board. What changed?
"I'd like to see some action on the Keytruda/CVA21 combo. Fortunately, in two weeks we should see some good news at ASCO, finally, on the results of the Yervoy/CVA combo trials that began early last year. Yervoy is a Bristol Myers immuno-therapy that is being superseded by its own Optivo with annual sales of one billion dollars. Would be very nice to see Cavatak provide major improvements as a combo drug with any of Yervoy, Optivo and Keytruda. Then a billion dollar valuation for VLA ($4 plus per share) won't look silly."
VLA Price at posting:
$1.69 Sentiment: Buy Disclosure: Held
